Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T21:31:44.902Z.
Calculation as of: 2026-10-06T21:31:44.902Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d6bd3278d76725a85d4cb05495e45b99d0fd89b23371e3701c8289362793e8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$723.18M
PS Ratio
N/A
TTM Avg
1076.18
3Y Avg
1003.10
5Y Avg
1003.10
Market Cap
$777.34M
PS Ratio
18.75
TTM Avg
12.05
3Y Avg
176.43
5Y Avg
968.45
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $747.61M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $742.70M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.37M | 3.05 | 2.14 | 2.44 | 3.85 |
| Sana Biotechnology, Inc. (SANA)vs › | $765.30M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $723.18M | N/A | 1076.18 | 1003.10 | 1003.10 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | N/A | 2.39 | 2.16 | 5.43 |
| Geron Corporation (GERN)vs › | $776.24M | 3.79 | 4.98 | 1623.75 | 1489.80 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.34M | 18.75 | 12.05 | 176.43 | 968.45 |
| Varex Imaging Corporation (VREX)vs › | $778.01M | 0.90 | 0.63 | 0.69 | 0.86 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-09 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
